NKGen Biotech Inc. Common... (NKGN)
NKGen Biotech Common Stock Statistics
Share Statistics
NKGen Biotech Common Stock has 45.28M shares outstanding. The number of shares has increased by 62.29% in one year.
| Shares Outstanding | 45.28M |
| Shares Change (YoY) | 62.29% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 22.65M |
| Failed to Deliver (FTD) Shares | 1.21K |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 561.27K, so 1.58% of the outstanding shares have been sold short.
| Short Interest | 561.27K |
| Short % of Shares Out | 1.58% |
| Short % of Float | 3.02% |
| Short Ratio (days to cover) | 1.27 |
Valuation Ratios
The PE ratio is -0.51 and the forward PE ratio is null. NKGen Biotech Common Stock's PEG ratio is -0.02.
| PE Ratio | -0.51 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -0.72 |
| P/FCF Ratio | -1.93 |
| PEG Ratio | -0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for NKGen Biotech Inc. Common Stock.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.05, with a Debt / Equity ratio of -0.34.
| Current Ratio | 0.05 |
| Quick Ratio | 0.05 |
| Debt / Equity | -0.34 |
| Total Debt / Capitalization | -51.38 |
| Cash Flow / Debt | -1.1 |
| Interest Coverage | -39.93 |
Financial Efficiency
Return on equity (ROE) is 1.41% and return on capital (ROIC) is 76.73%.
| Return on Equity (ROE) | 1.41% |
| Return on Assets (ROA) | -5.03% |
| Return on Capital (ROIC) | 76.73% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1,316,730.16 |
| Employee Count | 63 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 7K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -91.53% in the last 52 weeks. The beta is 0.45, so NKGen Biotech Common Stock's price volatility has been higher than the market average.
| Beta | 0.45 |
| 52-Week Price Change | -91.53% |
| 50-Day Moving Average | 0.39 |
| 200-Day Moving Average | 0.63 |
| Relative Strength Index (RSI) | 36.12 |
| Average Volume (20 Days) | 3.99M |
Income Statement
| Revenue | n/a |
| Gross Profit | -1.2M |
| Operating Income | -29.75M |
| Net Income | -82.95M |
| EBITDA | -28.54M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -5.38 |
Balance Sheet
The company has 26K in cash and 19.92M in debt, giving a net cash position of -19.89M.
| Cash & Cash Equivalents | 26K |
| Total Debt | 19.92M |
| Net Cash | -19.89M |
| Retained Earnings | -162.13M |
| Total Assets | 14.99M |
| Working Capital | -36.21M |
Cash Flow
In the last 12 months, operating cash flow was -21.95M and capital expenditures -48K, giving a free cash flow of -22M.
| Operating Cash Flow | -21.95M |
| Capital Expenditures | -48K |
| Free Cash Flow | -22M |
| FCF Per Share | -1.43 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NKGN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -3362.5% |
| FCF Yield | -302.09% |
Analyst Forecast
Currently there are no analyst rating for NKGN.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -29.44 |
| Piotroski F-Score | 2 |